NASDAQ:CGON CG Oncology (CGON) Stock Price, News & Analysis $26.93 -0.01 (-0.04%) As of 03:40 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CG Oncology Stock (NASDAQ:CGON) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CG Oncology alerts:Sign Up Key Stats Today's Range$26.00▼$27.9550-Day Range$15.59▼$28.5352-Week Range$14.80▼$46.99Volume1.30 million shsAverage Volume783,141 shsMarket Capitalization$2.05 billionP/E RatioN/ADividend YieldN/APrice Target$59.56Consensus RatingBuy Company OverviewCG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Read More… CG Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreCGON MarketRank™: CG Oncology scored higher than 42% of companies evaluated by MarketBeat, and ranked 833rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingCG Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCG Oncology has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CG Oncology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CG Oncology are expected to decrease in the coming year, from ($1.31) to ($1.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CG Oncology is -19.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CG Oncology is -19.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about CG Oncology's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.74% of the float of CG Oncology has been sold short.Short Interest Ratio / Days to CoverCG Oncology has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in CG Oncology has recently increased by 12.92%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCG Oncology does not currently pay a dividend.Dividend GrowthCG Oncology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted19.74% of the float of CG Oncology has been sold short.Short Interest Ratio / Days to CoverCG Oncology has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in CG Oncology has recently increased by 12.92%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment0.40 News SentimentCG Oncology has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for CG Oncology this week, compared to 4 articles on an average week.Search Interest7 people have searched for CGON on MarketBeat in the last 30 days. MarketBeat Follows4 people have added CG Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, CG Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,760.00 in company stock.Percentage Held by InstitutionsOnly 26.56% of the stock of CG Oncology is held by institutions.Read more about CG Oncology's insider trading history. Receive CGON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CG Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address CGON Stock News HeadlinesLeonard E. Post Sells 1,000 Shares of CG Oncology, Inc. (NASDAQ:CGON) StockApril 30 at 5:02 AM | insidertrades.comCantor Fitzgerald Reiterates Overweight Rating for CG Oncology (NASDAQ:CGON)April 30 at 1:47 AM | americanbankingnews.comM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big change. Make America Wealthy Again (M.A.W.A).April 30, 2025 | Paradigm Press (Ad)CG Oncology Stock Price, Quotes and Forecasts | NASDAQ:CGON | BenzingaApril 29 at 8:31 AM | benzinga.comWhy CG Oncology, Inc. (CGON) Surged on MondayApril 29 at 8:31 AM | msn.comBuy Rating for CG Oncology, Inc. Driven by Cretostimogene’s Potential in Bladder Cancer Treatment Amid BCG ShortageApril 29 at 8:27 AM | tipranks.comCG Oncology Shares Climb on Bladder-Cancer Treatment ResultsApril 28 at 11:13 PM | marketwatch.comCG Oncology Soars On Its Johnson & Johnson-Rivaling Cancer DrugApril 28 at 11:13 PM | msn.comSee More Headlines CGON Stock Analysis - Frequently Asked Questions How have CGON shares performed this year? CG Oncology's stock was trading at $28.68 at the beginning of 2025. Since then, CGON shares have decreased by 3.1% and is now trading at $27.80. View the best growth stocks for 2025 here. How were CG Oncology's earnings last quarter? CG Oncology, Inc. (NASDAQ:CGON) posted its earnings results on Tuesday, March, 25th. The company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by $0.11. The business earned $0.46 million during the quarter, compared to analysts' expectations of $0.11 million. CG Oncology had a negative trailing twelve-month return on equity of 18.97% and a negative net margin of 10,642.98%. When did CG Oncology IPO? CG Oncology (CGON) raised $380 million in an IPO on Thursday, January 25th 2024. The company issued 20,000,000 shares at a price of $19.00 per share. Who are CG Oncology's major shareholders? CG Oncology's top institutional shareholders include Bank of New York Mellon Corp (0.19%), Rhumbline Advisers (0.10%), China Universal Asset Management Co. Ltd. (0.02%) and Teacher Retirement System of Texas (0.01%). Insiders that own company stock include Hong Fang Song, Decheng Capital Global Life Sc, Corleen M Roche, Vijay Kasturi and Leonard E Post. View institutional ownership trends. How do I buy shares of CG Oncology? Shares of CGON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CG Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that CG Oncology investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA) and Tesla (TSLA). Company Calendar Last Earnings3/25/2025Today4/30/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CGON Previous SymbolNASDAQ:CGON CIK1991792 Webcgoncology.com Phone949-419-6203FaxN/AEmployees61Year FoundedN/APrice Target and Rating Average Stock Price Target$59.56 High Stock Price Target$75.00 Low Stock Price Target$23.00 Potential Upside/Downside+114.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($1.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-48,610,000.00 Net Margins-10,642.98% Pretax Margin-10,642.98% Return on Equity-18.97% Return on Assets-15.36% Debt Debt-to-Equity RatioN/A Current Ratio35.32 Quick Ratio35.32 Sales & Book Value Annual Sales$1.14 million Price / Sales1,860.26 Cash FlowN/A Price / Cash FlowN/A Book Value($1.94) per share Price / Book-14.33Miscellaneous Outstanding Shares76,217,000Free FloatN/AMarket Cap$2.12 billion OptionableOptionable Beta1.24 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:CGON) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CG Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CG Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.